Ring 1
Ring 2
Ring 3
Ring 4


Financing Rounds

  • Series C
  • Public
  • Exit
Round Led by Symbiosis
Round Led by Symbiosis
Round Led by Symbiosis

Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders.

surrozen View Website


  • Biologic


  • Circulatory & Metabolic Disease
  • Gastroenterology
  • Other

Development Status

  • Phase 1

Learn More About Surrozen